sleep-medicine
(8)
Alkermes
Alkermes spent decades teaching medicines to last longer. Now the neuroscience company is trying something harder: building a business around the brain's switches for addiction, psychosis and wakefulness.
Mosanna Therapeutics
Mosanna Therapeutics is a clinical-stage biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea (OSA). Rather than mechanically forcing the airway open like CPAP, MOS118 is a small molecule pan-K+ channel inhibitor that reactivates the body's own negative pressure reflex - stimulating pressure-sensing nerves in the nasopharynx to increase upper airway muscle tone and reduce apnea episodes. Founded in 2022 and headquartered in Redwood City, California with an office in Basel, Switzerland, the company launched publicly in June 2025 with an $80 million Series A to advance MOS118 through Phase 2.
Synthpop - Healthcare AI
Synthpop is a Cambridge, Massachusetts healthcare AI company building agentic automation that eliminates administrative bottlenecks across payer, provider and patient operations. Its platform combines document intelligence, payer-aware reasoning and conversational voice agents into one coordinated system that automates as much as 80% of healthcare back-office processes - referrals, prior authorizations, eligibility checks and claims follow-ups - by integrating directly with EHR, billing and e-prescribe systems. Founded in 2023 by Elad Ferber and Jan Jannink, the company has raised $23M total, including a $15M Series A in February 2026.
Wesper
Wesper is a New York-based sleep-health company that has built a wireless, wearable patch and cloud platform for clinical-grade, at-home sleep apnea testing. Founded in 2017 (originally as Tatch) by Dr. Amir Reuveny and Adi Mordechai, Wesper combines flexible printed electronics, machine learning, and a provider portal to replace the wires and single-night snapshots of traditional sleep labs with comfortable, repeatable, longitudinal testing. The FDA-cleared Wesper Lab lets patients test at home while giving physicians high-resolution data that correlates closely with in-lab polysomnography.
XII Medical
XII Medical is a Union City, California medical device company building a minimally invasive neuromodulation therapy for obstructive sleep apnea (OSA). Founded in 2017 and led by CEO Garrett Schwab, the company is developing an implantable platform designed to be smaller, more flexible and easier to implant than existing nerve-stimulation systems - an alternative for the estimated 425 million people worldwide with moderate-to-severe OSA who struggle with CPAP masks. Backed by Cleveland Clinic, Ajax Health, Omega Funds and Intuitive Ventures, XII Medical closed a $45M Series B in August 2024 to fund product and clinical development.
Sleep Reset
Sleep Reset is a San Francisco digital sleep clinic that brings the methods of an in-person sleep center to a phone. Built around Cognitive Behavioral Therapy for Insomnia (CBT-I), it pairs each user with a human sleep coach and a personalized, multi-week program instead of pills. Founded by serial entrepreneur Yunha Kim after her own years-long battle with insomnia and sleep apnea, the program was developed with researchers from Stanford, Yale and other institutions, and is used by thousands of people seeking a no-pill path to better sleep.
Beacon Biosignals
Beacon Biosignals is a Boston-based neurotechnology company that pairs FDA-cleared wearable EEG hardware with AI to turn brain electrical activity - especially during sleep - into scalable, at-home neurodiagnostics. Its platform powers drug development, clinical trials, and precision medicine across neurology, psychiatry, and sleep medicine.
Jacob Donoghue
Jacob Donoghue is a physician-scientist and the co-founder and CEO of Beacon Biosignals, a Boston company applying machine learning to EEG brain data to build neurobiomarkers for psychiatric, neurological, and sleep disorders. Trained with an MD from Harvard Medical School and a PhD in neuroscience from MIT, he started Beacon in 2019 on the bet that decades of overlooked brainwave recordings could be turned into a precision-medicine engine for drug development and diagnosis. Under his leadership the company has raised over $116M, secured FDA clearance for a wearable EEG headband, acquired home sleep-testing firm CleveMed, and partnered with more than half of the world's top ten biopharma companies.